856 | MARSUN, A PHASE III, MULTICENTER, OPEN LABEL, RANDOMIZED STUDY INVESTIGATING MOSUNETUZUMAB‐LENALIDOMIDE VERSUS INVESTIGATOR CHOICES IN R/R MARGINAL ZONE LYMPHOMAS
Sylvain Carras(Centre National de la Recherche Scientifique), Catherine Thiéblemont(Université Paris Cité), Stefano Luminari(University of Modena and Reggio Emilia), Christian Buske(University Hospital Ulm), María Gomes da Silva(Instituto Português de Oncologia Francisco Gentil), Eve Gehlkopf(The Lymphoma Academic Research Organisation), Marc André(CHU Dinant Godinne UCL Namur), M. Dreyling(Ludwig-Maximilians-Universität München), F. Morcshhauser(Centre Hospitalier Universitaire de Lille), G. Cartron(Centre Hospitalier Universitaire de Montpellier), A. Conconni(Ospedale degli Infermi), Céline Row(The Lymphoma Academic Research Organisation)
Cited by 1
Related Papers
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|604
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523